Market Closed - Nasdaq 04:00:00 2024-05-02 pm EDT 5-day change 1st Jan Change
34.55 USD +3.66% Intraday chart for Surmodics, Inc. +32.02% -4.95%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Barrington Ups Price Target on SurModics to $71 From $70, Maintains Outperform Rating MT
Top Midday Gainers MT
Transcript : Surmodics, Inc., Q2 2024 Earnings Call, May 01, 2024
Earnings Flash (SRDX) SURMODICS Reports Q2 Revenue $32M, vs. Street Est of $28.8M MT
Earnings Flash (SRDX) SURMODICS Reports Q2 EPS $0.07, vs. Street Est of $-0.32 MT
Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2024 CI
Surmodics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 CI
North American Morning Briefing : Traders Wait for -2- DJ
Barrington Trims Price Target on SurModics to $70 From $71, Keeps Outperform Rating MT
Needham Adjusts SurModics' Price Target to $47 From $44, Maintains Buy Rating MT
Surmodics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Transcript : Surmodics, Inc., Q1 2024 Earnings Call, Feb 01, 2024
(SRDX) SURMODICS Forecasts Fiscal Year 2024 Revenue Range $117M - $121M MT
Earnings Flash (SRDX) SURMODICS Reports Q1 Revenue $30.6M, vs. Street Est of $29.6M MT
Earnings Flash (SRDX) SURMODICS Reports Q1 EPS $0.00, vs. Street Est of $-0.30 MT
Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024 CI
Surmodics, Inc. Announces Successful Early Clinical Use of its Pounce LP Thrombectomy System CI
Surmodics, Inc. Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium CI
Surmodics, Inc. Announces 24-Month Data from the Swing Trial Presented At VEITHsymposium CI
Barrington Ups Price Target on SurModics to $71 From $69 After Better-than-Expected Q4/23 Results, Keeps Outperform Rating MT
Transcript : Surmodics, Inc., Q4 2023 Earnings Call, Nov 08, 2023
(SRDX) SURMODICS Expects Fiscal Year 2024 Revenue Range $116M - $121M MT
Earnings Flash (SRDX) SURMODICS Reports Q4 Revenue $28M, vs. Street Est of $26.3M MT
Earnings Flash (SRDX) SURMODICS Reports Q4 EPS $0.53, vs. Street Est of $0.17 MT
Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024 CI
Chart Surmodics, Inc.
More charts
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company's segments include Medical Device and IVD. The Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral, coronary and structural heart. It manufactures vascular intervention medical devices, including drug-coated balloons, and radial access balloon catheters and guide sheaths. The IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
34.55 USD
Average target price
58.25 USD
Spread / Average Target
+68.60%
Consensus
  1. Stock Market
  2. Equities
  3. SRDX Stock
  4. News Surmodics, Inc.
  5. Barrington Research Raises PT on SurModics to $69 From $60, as Valuation Increases For SurVeil DCB Program After US FDA Approval; Maintains Outperform Rating